{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:03:24Z","timestamp":1785488604784,"version":"3.56.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Primary aldosteronism (PA) has traditionally been considered a rare cause of secondary hypertension, but growing evidence supports a broader continuum of renin-independent aldosterone production extending into normotensive and mildly hypertensive populations. Subclinical primary aldosteronism (SPA) has emerged as a conceptual framework describing this milder phenotype. However, a universally accepted definition of SPA remains lacking, and consensus diagnostic criteria have yet to be established. This review synthesizes current evidence regarding SPA, including its epidemiology, pathophysiology, clinical implications, diagnostic challenges, and potential therapeutic strategies. Low-renin phenotypes are observed in a substantial proportion of individuals, although the true prevalence of SPA remains uncertain due to the lack of consensus diagnostic criteria. Observational studies have associated SPA with adverse cardiovascular and renal outcomes, including arterial stiffness, adverse cardiac remodeling, major adverse cardiovascular events, albuminuria, and chronic kidney disease progression, with effects not fully explained by blood pressure elevation alone. Conventional screening strategies based on the aldosterone-to-renin ratio have limitations in detecting this subclinical spectrum. Mineralocorticoid receptor antagonists and aldosterone synthase inhibitors represent hypothesis-generating therapeutic strategies, although prospective interventional evidence in SPA populations is lacking. At present, SPA should be regarded as an emerging risk-associated biochemical phenotype rather than an established disease category, pending prospective validation. Future studies are needed to determine whether consensus diagnostic criteria can be established and to validate clinically applicable screening strategies for this emerging endocrine phenotype.<\/jats:p>","DOI":"10.3389\/fendo.2026.1899618","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:49:47Z","timestamp":1785487787000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Subclinical primary aldosteronism: toward a conceptual framework linking primary aldosteronism and low-renin hypertension"],"prefix":"10.3389","volume":"17","author":[{"given":"Chan Ho","family":"Park","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dong-A University Hospital","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e220249","DOI":"10.1530\/JOE-22-0249","article-title":"Mineralocorticoid receptor signalling in primary aldosteronism","volume":"259","author":"Yang","year":"2023","journal-title":"J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2014.125","article-title":"The renin-angiotensin-aldosterone system and calcium-regulatory hormones","volume":"29","author":"Vaidya","year":"2015","journal-title":"J Hum Hypertens"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.125.076085","article-title":"Subclinical primary aldosteronism: a potential new target in cardiovascular prevention","volume":"152","author":"Vongpatanasin","year":"2025","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.124.073507","article-title":"Subclinical primary aldosteronism and major adverse cardiovascular events: a longitudinal population-based cohort study","volume":"152","author":"Goupil","year":"2025","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.20945\/2359-4292-2025-0400","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/s2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3803\/enm.2021.101","article-title":"The genotype-based morphology of aldosterone-producing adrenocortical disorders and their association with aging","volume":"36","author":"Gao","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2025.06.797","article-title":"Prevalence of low-renin hypertension: systematic review and meta-analysis of 60 studies including 11,781 participants","volume":"41","author":"Chauhan","year":"2023","journal-title":"J Hypertens"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae113","article-title":"Prevalence and characteristics of low-renin hypertension in a primary care population","volume":"8","author":"Shah","year":"2024","journal-title":"J Endocr Soc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an international human physiology study","volume":"109","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3353","article-title":"Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension","volume":"98","author":"Markou","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101399","article-title":"The spectrum of low-renin hypertension","volume":"34","author":"Buffolo","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.20945\/2359-4292-2025-0400","article-title":"Differential natriuretic peptide, ACTH, and angiotensin II responses to distinguish subclinical primary aldosteronism from low-renin essential hypertension","volume":"110","author":"Parisien-La Salle","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1505529112","article-title":"Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands","volume":"112","author":"Nishimoto","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4255","article-title":"Adrenal nodularity and somatic mutations in primary aldosteronism","volume":"99","author":"Dekkers","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169042","article-title":"Clinical translationality of KCNJ5 mutation in aldosterone producing adenoma","volume":"23","author":"Kitamoto","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00134","article-title":"Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals","volume":"1","author":"Omata","year":"2017","journal-title":"J Endocr Soc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2010","article-title":"Adrenocortical zonation in humans under normal and pathological conditions","volume":"95","author":"Nishimoto","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat Genet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2716","article-title":"Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension","volume":"45","author":"Azizan","year":"2013","journal-title":"Nat Genet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.05.005","article-title":"Genetic and genomic mechanisms of primary aldosteronism","volume":"26","author":"Fernandes-Rosa","year":"2020","journal-title":"Trends Mol Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1736534","DOI":"10.3389\/fendo.2025.1736534","article-title":"The adrenal gland and primary aldosteronism: anatomy, steroidogenesis, regulation, and genetic insights","volume":"16","author":"Long","year":"2026","journal-title":"Front Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9040409","article-title":"Genetics of primary aldosteronism: molecular basis of somatic and germline mutations driving adrenal cell fate and aldosterone production","volume":"46","author":"Itcho","year":"2023","journal-title":"Hypertens Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.009232","article-title":"Aldosterone and cardiovascular disease in patients with primary aldosteronism","volume":"7","author":"Morisaki","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.21983","article-title":"Long-term follow-up of patients with elevated aldosterone-to-renin ratio but negative confirmatory test: the progression of primary aldosteronism phenotypes","volume":"81","author":"Buffolo","year":"2024","journal-title":"Hypertension"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.09.008","article-title":"Plasma aldosterone levels and aldosterone-to-renin ratios are associated with endothelial dysfunction in young to middle-aged subjects","volume":"219","author":"Hannemann","year":"2011","journal-title":"Atherosclerosis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"key":"B36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamacardio.2026.0068","article-title":"Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study","volume":"11","author":"Lassen","year":"2026","journal-title":"JAMA Cardiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.126.26238","article-title":"Primary aldosteronism and chronic kidney disease: mechanisms, outcomes, and treatment","volume":"30","author":"Hundemer","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jch.70102","article-title":"Universal screening for primary aldosteronism in hypertensive patients: a 2025 Taipei positional paper","volume":"27","author":"Lin","year":"2025","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41371-023-00875-1","article-title":"Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society","volume":"38","author":"Faconti","year":"2024","journal-title":"J Hum Hypertens"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12020-022-03084-x","article-title":"Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism in primary care","volume":"77","author":"Ariens","year":"2022","journal-title":"Endocrine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01041","article-title":"Age-related cutoffs of plasma aldosterone\/renin concentration for primary aldosteronism screening","volume":"103","author":"Guo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1007\/978-3-030-44628-4_13-1","article-title":"Bilateral and unilateral primary aldosteronism: towards precision medicine in primary aldosteronism","volume":"21","author":"Zennaro","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1159\/000548494","article-title":"Finerenone: evidence for benefit in early stages of cardiovascular-kidney-metabolic syndrome","volume":"15","author":"M\u00e1rquez","year":"2025","journal-title":"Cardiorenal Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1476029","DOI":"10.3389\/fcvm.2024.1476029","article-title":"A comprehensive review of finerenone\u2014a third\u2011generation non\u2011steroidal mineralocorticoid receptor antagonist","volume":"11","author":"Zhai","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.124.071452","article-title":"Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial","volume":"151","author":"Hu","year":"2025","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf099","article-title":"Real-world outcomes of finerenone in primary aldosteronism","volume":"192","author":"Uslar","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"20406223241239775","DOI":"10.1177\/20406223241239775","article-title":"Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta\u2011analysis","volume":"15","author":"Ho","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.80.suppl_1.113","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1899618\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:49:48Z","timestamp":1785487788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1899618\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":55,"alternative-id":["10.3389\/fendo.2026.1899618"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1899618","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1899618"}}